The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Cilta-cel in earlier lines of therapy for R/R multiple myeloma
Roberto Mina, MD, University of Turin, Turin, Italy, briefly discusses the use of ciltacabtagene autoleucel (cilta-cel) in patients with relapsed/refractory (R/R) multiple myeloma (MM), referencing the CARTITUDE-1 (NCT03548207) and CARTITUDE-4 (NCT04181827) trials. CARTITUDE-1 indicated that this CAR T-cell therapy is efficacious in heavily pre-treated patients, and CARTITUDE-4 aimed to investigate whether the same benefits to survival outcomes are seen when administering cilta-cel in earlier lines of treatment. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Janssen, Sanofi, Takeda
Honoraria: Janssen, Pfizer, Amgen, Takeda, Celgene
Membership on Board of Directors or advisory committee: Janssen, Bristol Myers Squibb, Amgen, Takeda, Celgene
